B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg The double-blind

The double-blind

inhibited cell proliferation (IC50 = 31-125 nM) primarily in a cytostatic manner in cell lines that overexpress EGF-R or c-erbB-2

ADP668 is currently under clinical trial for diabetes

FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production

Inhibition of this enzyme's activity by azoles results in decreased amounts of ergosterol

B-HT 920 - CAS# 36085-73-1 Size:Solid 2 mg The double-blindTalipexole, also known as B HT920 and Domnin, is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996. As of December 2014 it was not approved for marketing in the US nor in Europe. Talipexole is a D2 dopamine receptor agonist and interacts both pre and post synaptic receptors. It also is an 2 adrenergic agonist. The main side effects are drowsiness, dizziness,